A Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 09 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs RO-7565020 (Primary) ; RO-7565020 (Primary) ; Entecavir; Tenofovir alafenamide; Tenofovir disoproxil fumarate
Indications Hepatitis B
Focus Adverse reactions; First in man
Sponsors Roche

07 Jan 2025 Status changed from recruiting to discontinued. (Reason the study was stopped: The Sponsor decided to discontinue the development of RO7565020 and as a result the BP44118 study was terminated).
08 Jul 2024 Planned End Date changed from 1 Feb 2027 to 13 May 2026.
08 Jul 2024 Planned primary completion date changed from 1 Feb 2027 to 13 May 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com